Skip to main content
. 2023 Mar 21;28(7):e488–e492. doi: 10.1093/oncolo/oyad024

Table 1.

Patient characteristics prior to initiating alpelisib (N = 92).

N (%)
Age
 75-94 years 9 (9.8)
 55-74 years 22 (23.9)
 Less than 55 years 61 (66.3)
Body mass index*
 Obese 33 (35.9)
 Overweight 29 (31.5)
 Normal 23 (25.0)
 Lean 7 (7.6)
Glycemic history
 Diabetes 31 (33.7)
 Pre-diabetes only 9 (9.8)
 Normoglycemia 52 (56.5)
Diagnosis of hypertension
 Present 49 (53.3)
 Absent 43 (46.7)
Diagnosis of hyperlipidemia
 Present 38 (41.3)
 Absent 54 (58.7)
Self-reported ancestry
 Asian 12 (13.0)
 Hispanic/Latino 14 (15.2)
 African/Black 8 (8.7)
 Hawaiian/Pacific Islander 1 (1.1)
 Other 2 (2.2)
 Non-Hispanic White 46 (50.0)
 Unknown/decline to state 9 (9.8)

*As described in the Methods, Results, and Supplementary Table S1, for n = 64 subjects it was necessary to estimate the pre-alpelisib value of BMI from a post-alpelisib value in their medical chart. Lean was defined as BMI < 20, normal was defined as BMI 20 to <25 (BMI 20 to <23 for Asians), overweight was defined as BMI 25 to <30 (BMI 23 to <27.5 for Asians), and obese was defined as BMI ≥30 (BMI ≥27.5 for Asians).5,6